Companies

Alliance is a specialty pharmaceutical company based in the United Kingdom. The company has a strong track record of acquiring the rights to established niche brands and owns or shares the rights to 34 branded prescribed pharmaceutical products. Revenues in the year ending December 2006 were £17.3 million, an increase of 19.7% over the 12 months to December 2005. Like for like growth was 7.7% with the additional growth derived from brands acquired in the period.

Alliance maintains strategic and controlling functions with a management team possessing large pharmaceutical company experience. More capital intensive functions are outsourced to maximise efficiency and profitability.

The core of Alliances' activities have been in the United Kingdom and the Republic of Ireland. However recent acquisitions have enabled an international expansion to growing markets.

Alliance has acquired brands from leading pharmaceutical companies such as Novartis, Procter and Gamble, Lilly and Pfizer. Alliance is constantly considering a number of in-licensing opportunities. At this stage we will look at possibilities in all therapy areas.

If you are seeking a UK and Europe market entry partner, Alliance's sales, marketing and regulatory expertise can help you navigate the whole process from marketing authorisation submission to field force deployment. Alliance will expand infrastructure to fit the opportunity.

Alliance has two products in development: Posidorm is an unqiue formulation of melatonin for sleep disorders and Isprelor is a 25mcg formulation of misoprostol specially developed for induction of labour. We are interested in discussions with potential co-development and out-licensing partners.

Alliance focuses on prescription branded medicines in the human medical and dental sectors, primarily in the UK and Ireland with progressive and considered development into selective international markets.

We have a number of clear business strategies for growth:

1. Acquisition of established brands for continued commercial success (with a focus on Rx brands).
2. UK and European market entry partner for novel in-licensed technologies and therapies
3. Expanded international marketing of acquired technologies and therapies
4. Selected development of products for co-development and out-licensing

Melatonin, a natural hormone, secreted by the pineal gland, is the regulator of normal sleep and its deficiency or imbalance is potentially a cause of many sleeping disorders. Posidorm

John Dawson (Chief Executive Officer and Director)
Mr. Dawson founded Alliance in 1996. He gained multi-disciplinary experience in the pharmaceutical industry over 30 years. John held various senior roles at Sandoz (now Novartis) as director of finance and administration and deputy managing director. John has a BSc (Pharmacy) and an MSc (Finance) from the London Business School.

Richard Wright (Finance Director & Company Secretary and Director)
Mr. Wright joined the Board of Alliance in 2007. He is a Chartered Accountant with over 15 years of experience in financial roles across a variety of sectors. Richard read Mathematics at Robinson College, Cambridge and qualified as an accountant with Ernst & Young before joining Somerfield. More recently, he held senior finance positions at FirstGroup and Parragon Publishing.

Tony Booley (Sales & Marketing Director)
Mr. Booley joined Alliance in 1998. He has had around 30 years' sales and marketing experience in the pharmaceutical and healthcare industries, with positions at Leo Pharma, Glaxo Wellcome (now GSK) and Getinge Industrier. He has considerable senior management experience in the UK and internationally, including overseas positions in India and the Middle East. Tony graduated in Physiology from the University of Dundee in 1979, gained an MBA from Warwick in 1990 and is a Chartered Marketer.

Mark Tomlinson (Medical Director and Director)
Mr. Tomlison joined the Board of Alliance in 2007. He is a pharmaceutical physician with over 14 years' experience in clinical research and development, and in medical affairs in UK, Europe, US and worldwide settings. He has held positions at Bristol Myers Squibb and Sanofi and was most recently medical director at Sequani, a contract research organisation. Mark graduated from the University of Wales College of Medicine in 1985, was awarded membership of the Royal College of General Practitioners in 1989, the Diploma in Pharmaceutical Medicine in 1996 and Membership of the Faculty of Pharmaceutical Medicine (Royal Colleges of Physicians) in 2002.

Paul Ranson (Non-Executive Director)
Mr. Ranson has worked in a legal capacity in the pharmaceutical sector for over 25 years. He spent the early years of his career as an in-house lawyer for Smith Kline & French and Merck. He is a partner in the international law firm Fasken Martineau Stringer Saul and specialises exclusively in the commercial and regulatory aspects of life sciences.

Andrew Smith (Non-Executive Director)
Mr. Smith joined the Board of Alliance in 2006. He has held various senior positions in the pharmaceutical industry throughout the UK and overseas having been managing director and senior vicepresident of SmithKline Beecham (now GSK), chief executive of Cerebrus plc until its sale and president international medical marketing services with Parexel International. He is non-executive chairman of Fishawack Communications Ltd, a specialist Medical Educational Services company, and non-executive director of the NHS Institute for Innovation and Improvement. Andrew is currently a consultant with Navitas BioPharma Consulting.

Michael R B Gatenby (Chairman)
Mr. Gatenby joined the Board of Alliance as non-executive Chairman in 2004. He had a successful career in corporate finance for over 25 years, having been a director of Hill Samuel and Co and vice-chairman of Charterhouse Bank. Michael graduated in Law from Trinity Hall, Cambridge in 1966 and qualified as a Chartered Accountant in 1969 with Peat, Marwick, Mitchell (now KPMG).

John Dawson (Chief Executive Officer and Director)
Mr. Dawson founded Alliance in 1996. He gained multi-disciplinary experience in the pharmaceutical industry over 30 years. John held various senior roles at Sandoz (now Novartis) as director of finance and administration and deputy managing director. John has a BSc (Pharmacy) and an MSc (Finance) from the London Business School.

Richard Wright (Finance Director & Company Secretary and Director)
Mr. Wright joined the Board of Alliance in 2007. He is a Chartered Accountant with over 15 years of experience in financial roles across a variety of sectors. Richard read Mathematics at Robinson College, Cambridge and qualified as an accountant with Ernst & Young before joining Somerfield. More recently, he held senior finance positions at FirstGroup and Parragon Publishing.

Tony Booley (Sales & Marketing Director)
Mr. Booley joined Alliance in 1998. He has had around 30 years' sales and marketing experience in the pharmaceutical and healthcare industries, with positions at Leo Pharma, Glaxo Wellcome (now GSK) and Getinge Industrier. He has considerable senior management experience in the UK and internationally, including overseas positions in India and the Middle East. Tony graduated in Physiology from the University of Dundee in 1979, gained an MBA from Warwick in 1990 and is a Chartered Marketer.

Mark Tomlinson (Medical Director and Director)
Mr. Tomlison joined the Board of Alliance in 2007. He is a pharmaceutical physician with over 14 years' experience in clinical research and development, and in medical affairs in UK, Europe, US and worldwide settings. He has held positions at Bristol Myers Squibb and Sanofi and was most recently medical director at Sequani, a contract research organisation. Mark graduated from the University of Wales College of Medicine in 1985, was awarded membership of the Royal College of General Practitioners in 1989, the Diploma in Pharmaceutical Medicine in 1996 and Membership of the Faculty of Pharmaceutical Medicine (Royal Colleges of Physicians) in 2002.

Paul Ranson (Non-Executive Director)
Mr. Ranson has worked in a legal capacity in the pharmaceutical sector for over 25 years. He spent the early years of his career as an in-house lawyer for Smith Kline & French and Merck. He is a partner in the international law firm Fasken Martineau Stringer Saul and specialises exclusively in the commercial and regulatory aspects of life sciences.

Andrew Smith (Non-Executive Director)
Mr. Smith joined the Board of Alliance in 2006. He has held various senior positions in the pharmaceutical industry throughout the UK and overseas having been managing director and senior vicepresident of SmithKline Beecham (now GSK), chief executive of Cerebrus plc until its sale and president international medical marketing services with Parexel International. He is non-executive chairman of Fishawack Communications Ltd, a specialist Medical Educational Services company, and non-executive director of the NHS Institute for Innovation and Improvement. Andrew is currently a consultant with Navitas BioPharma Consulting.